BMY:
The current market price is 54.17, reflecting no percentage change from the previous close.
Support and Resistance Levels
Current support levels are 52.98, 52.41, and 52.01, while resistance levels are 54.60, 55.00, and 55.50. The pivot point is 54.17.
Indicators
The RSI is 62.54, indicating a moderately bullish trend. ATR shows low volatility at 0.05. The Parabolic SAR suggests bullish trends; moving averages support upward momentum.
Market Sentiment
The price is at the pivot point (54.17), indicating potential for bullish momentum supported by indicators.
BMY Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Bristol-Myers Squibb Company, trading under the symbol BMY on the NYSE, is a global biopharmaceutical leader committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Founded in 1887 and headquartered in New York City, the company has a rich history that underscores its dedication to scientific excellence and patient care. With a focus on oncology, immunology, cardiovascular disease, and fibrosis, Bristol-Myers Squibb leverages its robust research capabilities and extensive pipeline to address some of the world's most complex health challenges.
Market Position
Bristol-Myers Squibb has solidified its standing as a formidable player in the biopharmaceutical sector, ranking among the top companies in the industry. With a market capitalization consistently exceeding $150 billion, the company has remained competitive through strategic acquisitions and partnerships that enhance its therapeutic offerings. The company’s flagship products, including Opdivo and Eliquis, have established strong market share, driving significant revenue streams. Bristol-Myers Squibb's commitment to innovation is exemplified by its extensive portfolio of late-stage development candidates that are poised to address unmet medical needs across various therapeutic areas.
Key Financial Highlights
In recent years, Bristol-Myers Squibb has demonstrated robust financial performance, characterized by strong revenue growth and an impressive net income margin. The company reported revenues of approximately $47.5 billion in the last fiscal year, reflecting a year-over-year increase driven by solid sales of key products. With a focus on research and development, Bristol-Myers Squibb allocates a significant portion of its budget to innovative therapies, investing over $6 billion in R&D annually. The company maintains a strong balance sheet with significant cash reserves, providing a solid foundation for future growth and expansion opportunities.
Conclusion
Overall, Bristol-Myers Squibb exemplifies a commitment to innovation and excellence in healthcare. With its strong market position, strategic growth initiatives, and ongoing focus on research and development, BMY is well-positioned to continue making a positive impact in the biopharmaceutical arena.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
